Biodesix Company Insiders
BDSX Stock | USD 1.41 0.04 2.92% |
Slightly above 84 percent of Biodesix's insiders are selling. The analysis of the overall insider sentiment regarding Biodesix suggests that a fairly large number of insiders are terrified. Biodesix employs about 217 people. The company is managed by 18 executives with a total tenure of roughly 507 years, averaging almost 28.0 years of service per executive, having 12.06 employees per reported executive.
Biodesix's Insider Buying Vs Selling
16
Selling | Buying |
Latest Trades
2024-11-05 | John Patience | Acquired 75000 @ 1.38 | View | ||
2024-08-12 | Scott Hutton | Disposed 963 @ 1.57 | View | ||
2024-08-09 | Scott Hutton | Disposed 2781 @ 1.6 | View | ||
2024-05-09 | Gary Anthony Pestano | Disposed 434 @ 1.48 | View | ||
2024-02-12 | Scott Hutton | Disposed 29708 @ 1.66 | View | ||
2024-02-09 | Gary Anthony Pestano | Disposed 5862 @ 1.92 | View |
Monitoring Biodesix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Biodesix |
Biodesix Management Team Effectiveness
The company has return on total asset (ROA) of (0.2279) % which means that it has lost $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3182) %, meaning that it created substantial loss on money invested by shareholders. Biodesix's management efficiency ratios could be used to measure how well Biodesix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.72 in 2024. Return On Capital Employed is likely to drop to -0.66 in 2024. At this time, Biodesix's Non Currrent Assets Other are fairly stable compared to the past year. Other Assets is likely to rise to about 7.2 M in 2024, whereas Total Assets are likely to drop slightly above 86.1 M in 2024.Common Stock Shares Outstanding is likely to rise to about 86.2 M in 2024, whereas Net Loss is likely to drop (61.8 M) in 2024.
Biodesix Workforce Comparison
Biodesix is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 282. Biodesix totals roughly 217 in number of employees claiming about 77% of equities under Health Care industry.
Biodesix Profit Margins
The company has Profit Margin (PM) of (0.67) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.47) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.47.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.69 | 0.6766 |
|
|
Biodesix Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biodesix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biodesix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biodesix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kennedy Lawrence T. Jr few days ago Acquisition by Kennedy Lawrence T. Jr of 51200 shares of Biodesix at 1.365 subject to Rule 16b-3 | ||
Vazquez Chris over two weeks ago Acquisition by Vazquez Chris of tradable shares of Biodesix subject to Rule 16b-3 | ||
Scott Hutton over two weeks ago Acquisition by Scott Hutton of 180926 shares of Biodesix at 1.46 subject to Rule 16b-3 | ||
Robin Cowie over three weeks ago Disposition of 327 shares by Robin Cowie of Biodesix subject to Rule 16b-3 | ||
Gary Pestano over two months ago Disposition of 434 shares by Gary Pestano of Biodesix at 1.4795 subject to Rule 16b-3 | ||
Robin Cowie over three months ago Disposition of 724 shares by Robin Cowie of Biodesix at 1.601 subject to Rule 16b-3 | ||
Patience John over three months ago Disposition of 5435 shares by Patience John of Biodesix subject to Rule 16b-3 | ||
Watts Charles M over three months ago Disposition of 26368 shares by Watts Charles M of Biodesix subject to Rule 16b-3 |
Biodesix Notable Stakeholders
A Biodesix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biodesix often face trade-offs trying to please all of them. Biodesix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biodesix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Scott Hutton | CEO President | Profile | |
Robin Cowie | Secretary CFO | Profile | |
Christopher Vazquez | Controller VP | Profile | |
James MD | CoChief Officer | Profile | |
Matt Stauffer | VP Sales | Profile | |
Dr III | Chief Officer | Profile | |
Ryan Siurek | Chief Officer | Profile | |
Heinrich Rder | Founder CTO | Profile | |
Paul Beresford | Chief Officer | Profile | |
Steven Springmeyer | CoChief Officer | Profile | |
Robert Cawthorn | Founder Emeritus | Profile | |
Jeffrey Bojar | VP Affairs | Profile | |
Kieran OKane | Chief Officer | Profile | |
Gary Pestano | Chief Officer | Profile | |
Mark DeBlock | Vice Sales | Profile | |
Robbie Lunt | Senior Marketing | Profile | |
Bobbi Coffin | Chief Officer | Profile | |
Jessica Olbricht | Senior Resources | Profile |
About Biodesix Management Performance
The success or failure of an entity such as Biodesix often depends on how effective the management is. Biodesix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biodesix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biodesix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.68) | (0.72) | |
Return On Capital Employed | (0.63) | (0.66) | |
Return On Assets | (0.53) | (0.55) | |
Return On Equity | (11.39) | (10.82) |
Please note, the imprecision that can be found in Biodesix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biodesix. Check Biodesix's Beneish M Score to see the likelihood of Biodesix's management manipulating its earnings.
Biodesix Workforce Analysis
Traditionally, organizations such as Biodesix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biodesix within its industry.Biodesix Manpower Efficiency
Return on Biodesix Manpower
Revenue Per Employee | 226.2K | |
Revenue Per Executive | 2.7M | |
Net Loss Per Employee | 240.3K | |
Net Loss Per Executive | 2.9M | |
Working Capital Per Employee | 28.9K | |
Working Capital Per Executive | 348.2K |
Additional Tools for Biodesix Stock Analysis
When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.